[Report] The Blood Industry TOC

The Blood Industry
Chapter 1 - SUMMARY
- MAJOR FINDINGS
SUMMARY TABLE: U.S. BLOOD MARKET, THROUGH 2012 ($ MILLIONS)
SUMMARY FIGURE: U.S. BLOOD MARKET, 2007 AND 2012 ($ MILLIONS)
Chapter 2 - OVERVIEW
- THE BLOOD INDUSTRY
- MARKET STRUCTURE AND SIZE
TABLE 1 U.S. BLOOD PRODUCTS AND COLLECTION AND PROCESSING PRODUCTS MARKET, THROUGH 2012 ($ MILLIONS)
- HISTORY OF THE BLOOD INDUSTRY
TABLE 2 TIMELINE OF THE BLOOD INDUSTRY
TABLE 2 (CONTINUED)
- BLOOD AND ITS COMPONENTS
  - PLASMA
TABLE 3 COMPOSITION OF BLOOD
- CELLULAR ELEMENTS
  - Red and White Blood Cells
  - Platelets
- IMMUNOGLOBULIN PRODUCTS
- THE DANGERS OF TRANSFUSED BLOOD
- TRANSFUSION ASSOCIATED RISKS
  - Diseases Contracted from Blood Transfusions and Related Identification Testing
- TABLE 4 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS
- TABLE 4 (CONTINUED)
  - HIV/AIDS
- TABLE 5 CBER-LICENSED HIV DONOR SCREENING TESTS
- TABLE 5 (CONTINUED)
  - Hepatitis A
  - Hepatitis B
- TABLE 6 CBER-LICENSED SCREENING TESTS FOR HEPATITIS B
  - Hepatitis C
- TABLE 7 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C
  - Hepatitis D
  - Hepatitis E
  - Human T Cell Lymphotropic Virus-(HTLV-I, -II)
- TABLE 8 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II
  - Cytomegalovirus
- TABLE 9 CBER-LICENSED SCREENING TESTS FOR CMV
- TABLE 9 (CONTINUED)
- TABLE 10 CBER-LICENSED SCREENING TESTS FOR WEST NILE
  - "Mad Cow Disease"-Creutzfeldt-Jakob Disease (CJD)
  - Syphilis
  - Chagas Disease
    - Chagas Disease (Continued)
    - Current Status of Blood Donor Screening for Chagas Disease
- EFFORTS TO CREATE A VIRUS-FREE BLOOD SUPPLY
  - Plasma Treatments
    - Trinitrobutyl Phosphate and Sodium Cholate
    - Methylene Blue-treated Plasma
  - Amatosalen HCL-Treated Plasma
  - Platelet Treatments
  - RBCs
- NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS
  - Negative Reactions from Blood ý (Continued)
- BLOOD/PLASMA COMPONENT RISKS
Chapter 3 - THE BLOOD MANAGEMENT SYSTEM: BLOOD COLLECTION, PROCESSING, AND USE
- BLOOD COLLECTION
  - ORGANIZATIONS COLLECTING BLOOD
    - For-profit Blood Collection
    - Plasma Collection Centers
      - National Donor Deferral Registry
    - Nonprofit Blood Collection
      - American Red Cross
      - Community Blood Banks
      - Hospitals
      - Other Blood Collection Sites
- BLOOD DONATION DEMOGRAPHICS
- DONOR RECRUITMENT AND REGULATIONS
- BLOOD SCREENING AND EVALUATION
- METHODS FOR COLLECTING BLOOD FROM A DONOR
  - Manual Collection
  - Automated Collection
    - Plasmapheresis
    - Plateletpheresis
    - Leukopheresis
    - Red Blood Cell Apheresis
- PLASMA COLLECTION
  - Commercial Nature of Plasmapheresis
  - Global Nature of the Plasma Industry
  - Plasma Fractionators
  - Distributors/Brokers
- BLOOD TYPING AND TESTING FOR DISEASES
  - Blood Typing
- TABLE 11 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS
- TABLE 11 (CONTINUED)
- TABLE 12 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS
  - Methods of Typing
    - Manual Blood Typing Methods
      - Slide/Tile Testing
      - Tube Testing
      - Microplate
    - Automated Blood Typing and Screening Methods
    - Blood Testing
      - Blood Storage
    - BLOOD PROCESSING
      - Preparation and Use of the Components
        
        Red Blood Cell Components
        Platelets
- BLOOD TRANSFUSIONS
  - Testing before Transfusion
  - Manual Crossmatch Techniques
    - Major Crossmatch
    - Minor Crossmatch
    - Antibody Screen
    - Coombs Test
- TYPES OF TRANSFUSIONS
  - Whole Blood
  - Packed Red Blood Cells
  - Platelets
  - Leukocytes
  - Fresh Frozen Plasma (FFP)
- TABLE 13 SELECTED USES OF FFP
  - Cryoprecipitate
  - Coagulation Factors
- TABLE 14 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE
  - Immune Serum Globulin/Intramuscular Immune Globulins (IMIG)/Intravenous Immune Globulin (IGIV)
  - Factor VIII
  - Factor IX and Factor IX Complex
  - Factor VIIa
  - Fibrin/Thrombin
  - Therapeutic Apheresis
- BLOOD MANAGEMENT ISSUES
  - AVAILABILITY ISSUES
  - BLOODLESS SURGERY
  - SAFETY ISSUES-RISK MANAGEMENT
- TABLE 15 FACTORS TO REDUCE RISKS OF TRANSFUSION-ASSOCIATED DISEASES
  - Better Donor Screening
  - Better Viral Screening Tests
  - Get More Repeat Donors
  - Develop Better Viral Inactivation Processes
  - Selective Use of Blood Derivative Products
Chapter 4 - REGULATION OF THE BLOOD BUSINESS
- REGULATION OF THE U.S. BLOOD BUSINESS
- TABLE 16 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY
- TABLE 16 (CONTINUED)
  - STATUTORY AUTHORITY OF THE FDA
    - Center for Biologics Evaluation and Research
      - Office of Regulatory Affairs (ORA)
      - Office of Biologics, the Division of Blood and Blood Products
- TABLE 17FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS
  - THE MAJOR REGULATIONS AND POLICY MATTERS CONCERNING THE U.S.BLOOD SUPPLY
    - The Clinical Laboratory Improvement Act of 1988 (CLIA)
    - The FDA' S Five Layers
    - The FDA Blood Action Plan
- TABLE 18 MAIN BLOOD REGULATION ISSUES IDENTIFIED BY THE FDA
- TABLE 18 (CONTINUED)
  - Team Biologics
- HOW REGULATIONS GET IMPLEMENTED
  - Inspecting Blood Banks and Plasma Collection Facilities
- TABLE 1914 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES
  - OTHER ORGANIZATIONS INVOLVED IN BLOOD REGULATION
    - National Heart, Lung, and Blood Institute (NHLBI)
    - Blood Diseases and Resources Program
- Occupational Safety and Health Administration (OSHA)
- Health Care Financing Administration (HCFA)
- The Department of Defense
- State Regulatory Agencies
VOLUNTARY REGULATION BY PROFESSIONAL AND TRADE ASSOCIATIONS
- American Association of Blood Banks
  - American Blood Resources Association
  - America' s Blood Centers (ABC)
  - PPTA: Plasma Products Therapeutics Association
- THE EUROPEAN UNION (EU) BLOOD DIRECTIVE
  - International Society for Blood Transfusion (ISBT) 128
- THE FUTURE OF BLOOD REGULATION
Chapter 5 - THE BLOOD AND BLOOD PRODUCTS MARKET
- DRIVING FORCES OF THE INDUSTRY
- FIGURE 1 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR TRANSFUSION
- MARKET OVERVIEW
- FIGURE 2 BLOOD MARKET COST AND PRICING ANALYSIS
  - BLOOD COLLECTION DATA
- TABLE 20 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2012 (MILLION UNITS/PTS.)
- FIGURE 3 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2005-2012 (MILLION UNITS/PTS.)
- TABLE 21 U.S. PLASMA COLLECTION DATA, THROUGH 2012 (MILLION UNITS/L)
- FIGURE 4 U.S. PLASMA COLLECTION DATA, 2005-2012 (MILLION UNITS/L)
  - CHANGING PATTERNS OF TRANSFUSION PROCEDURES
    - Leukoreduction
    - Impact of Autologous Donations
      - Types of Autologous Transfusions
      - Risks of PABD
  - PRICING OF BLOOD
- TABLE 22 COST OF BLOOD COMPONENTS, THROUGH 2012 ($)
  - National Blood Exchange (NBE)
  - RBCs and Leukoreduced RBCs
  - Platelets
    - Random Donor Platelets
    - Fresh Frozen Plasma (FFP)
    - Cryoprecipitate
    - Washed Cells
    - Deglycerolized Cells
    - Other Blood Components
      - Granulocytes
      - Gamma-Irradiated Blood
    - AVERAGE COST OF TRANSFUSION
- TABLE 23 AVERAGE COST OF TRANSFUSION TO PATIENT BY PRODUCT TYPE, 2007 ($)
  - PLASMA AND PLASMA-DERIVED PRODUCTS
    - Plasma Market Size
    - Plasma Therapeutic Products
- TABLE 24 U.S. MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE, THROUGH 2012 ($ MILLIONS)
- FIGURE 5 SHARE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2007 AND 2012 (%)
  - Albumin and Plasma Protein Fraction (PPF)
    - FDA Notification Regarding Safety of Albumin Administration in Critically Ill
    - Recombinant Human Albumin
    - Albumin Market Dynamics
- TABLE 25 CURRENTLY MARKETED ALBUMIN AND PLASMA PROTEIN FRACTION (PPF) PRODUCTS
  - Albumin and PPF Market Size
- TABLE 26 U.S. MARKET FOR HUMAN SERUM ALBUMIN AND PPF, THROUGH 2012 (UNITS, PRICE, AND VALUE)
  - Clotting Factors
- TABLE 27 BLOOD CLOTTING FACTORS
  - Hemophilia
- TABLE 28 WORLDWIDE AND U.S.HEMOPHILIA STATISTICS, 2007
  - Market Demand and Market Size
- TABLE 29 U.S. MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, THROUGH 2012 ($ MILLIONS)
- FIGURE 6 U.S. SHARE FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, 2007 AND 2012 (%)
  - Factor VIII
- TABLE 30 FDA-APPROVED FACTOR VIII PRODUCTS
- TABLE 30 (CONTINUED)
  - Factor VIII (Continued)
- TABLE 31 U.S. MARKET SHARE FACTOR VIII COMPANIES, 2007
- FIGURE 7 MARKET SHARE OF FACTOR VIII COMPANIES, 2007 (%)
  - Factor IX
- TABLE 32 FDA-APPROVED FACTOR IX PRODUCTS
  - Factor VIIa
  - Other Factors
    - Prothrombin Complex Concentrates
- TABLE 33 FDA-APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS
  - Fibrin Sealants and Thrombin
- TABLE 34 U.S. MARKET FOR FIBRIN/THROMBIN, THROUGH 2012 ($ MILLIONS)
  - Antithrombin III
- TABLE 35 U.S. MARKET FOR ANTITHROMBIN III-THROMBATE, THROUGH 2012 ($ MILLIONS)
  - Immunoglobulins
    - IVIG
- TABLE 36 SELECTED CONDITIONS TREATED BY IVIG
- TABLE 37 FDA-APPROVED IMMUNOGLOBULINS
  - Hyperimmunes
- TABLE 38 FDA-APPROVED HYPERIMMUNE IMMUNOGLOBULINS
- TABLE 38 (CONTINUED)
  - Other
  - IMIG
- Immunoglobulin Market Size
- TABLE 39 U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, THROUGH 2012 ($ MILLIONS)
- FIGURE 8 U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, 2007 AND 2012 ($ MILLIONS)
  - RSV
  - CMV Immunoglobulin
  - Hepatitis B Immune Globulin
  - RhoD Immunoglobulin
  - Tetanus Immunoglobulin (TIG)
  - Rabies Immunoglobulin
  - Varicella Immunoglobulin
  - Vaccinia Immune Globulin Intravenous (VIG)
  - Alpha-1-Proteinase Inhibitor
  - Alpha-1-Proteinase (Continued)
Chapter 6 - BLOOD TESTING AND TYPING MARKETS
- MARKET SIZE
- TABLE 40 VALUE U.S. BLOOD TYPING AND BLOOD SCREENING MARKET, THROUGH 2012 ($ MILLIONS)
- FIGURE 9 VALUE AND MARKET SHARE OF U.S. BLOOD TYPING AND BLOOD SCREENING MARKET, 2007 AND 2012 (%)
- TYPES OF TESTING
  - POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION
- TABLE 41 CBER-LICENSED PCR SCREENING TESTS
- TABLE 41 (CONTINUED)
  - NUCLEIC ACID AMPLIFICATION TEST (NAT)
- TABLE 42 CBER-LICENSED NAT DONOR SCREENING TESTS
IMMUNOASSAY
- TABLE 43 IMMUNOASSAY CBER-LICENSED SCREENING TESTS
- TABLE 43 (CONTINUED)
  - MARKET SIZE BLOOD TESTING PRODUCTS FOR DONOR SCREENING
- TABLE 44 AVERAGE COST OF DONOR BLOOD TESTING, 2007 AND 2012 ($ MILLIONS)
- TABLE 45 THE U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2012 ($ MILLIONS)
- FIGURE 10 U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE, 2007 AND 2012 ($ MILLIONS)
  - MARKET PARTICIPANTS DONOR SCREENING PRODUCTS
- TABLE 46 LIST OF SUPPLIERS DONOR SCREENING TESTS
  - BLOOD TYPING
    - MARKET SIZE BLOOD TYPING
- TABLE 47 THE U.S. BLOOD TYPING MARKET-INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2012 ($ MILLIONS)
  - MARKET STRUCTURE AND PARTICIPANTS
    - Manual Typing Methods
    - Automated Blood Typing
    - Immucor
    - Ortho
    - Olympus
- BLOOD COLLECTION/TRANSFUSION PRODUCTS AND PROCESSING EQUIPMENT AND SUPPLIES
- TABLE 48 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION/TRANSFUSION PRODUCTS, THROUGH 2012 ($ MILLIONS)
  - COLLECTION PRODUCTS
- TABLE 49 U.S. MARKET FOR COLLECTION PRODUCTS BY TYPE, THROUGH 2012 ($ MILLIONS)
  - PLASMA AND BLOOD COLLECTION EQUIPMENT
- TABLE 50 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION EQUIPMENT BY TYPE, THROUGH 2012 ($ MILLIONS)
- FIGURE 11 SHARE OF U.S. MARKET FOR BLOOD AND PLASMA COLLECTION PRODUCTS BY TYPE, 2007 AND 2012 (%)
- Blood Salvage
OTHER COLLECTION EQUIPMENT
- TABLE 51 U.S. MARKET FOR OTHER PLASMA COLLECTION PRODUCTS, THROUGH 2012 ($ MILLIONS)
- MARKET PARTICIPANTS
  - Haemonetics
    - PCS2
    - TCD Total Containment Unit
    - MCS+ 8150 System
    - Cell Saver System
    - OrthoPAT System
    - ACP 215 System
  - Baxter
  - Autopheresis-C
  - Alyx Component Collection System
  - CS-3000 Plus Blood Cell Separator
  - Amicus Separator
  - Gambro BCT
- PLASMA COLLECTION SETS
- TABLE 52 U.S. MARKET FOR PLASMA COLLECTION SETS, THROUGH 2012 ($ MILLIONS)
  - BLOOD BAGS
- TABLE 53 U.S. MARKET FOR BLOOD BAGS, THROUGH 2012 ($ MILLIONS)
  - TRANSFUSION PRODUCTS
- TABLE 54 U.S. MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2012 ($ MILLIONS)
  - Transfusion Sets
- TABLE 55 U.S. MARKET FOR TRANSFUSION SETS, THROUGH 2012 ($ MILLIONS)
  - Blood Filter Market
- TABLE 56 U.S. MARKET FOR FILTERS, THROUGH 2012 ($ MILLIONS)
  - Accessories
- TABLE 57 U.S. MARKET FOR TRANSFUSION ACCESSORIES, THROUGH 2012 ($ MILLIONS)
Chapter 7 - TECHNOLOGY
- CLASSICAL FRACTIONATION METHODS
  - COHN FRACTIONATION
- ADVANCED FRACTIONATION METHODS
- AMPLIFICATION METHODS
  - POLYMERASE CHAIN REACTION (PCR)
  - NUCLEIC AMPLIFICATION TECHNOLOGY (NAT)
- IMMUNOASSAY
  - ENZYME IMMUNOASSAY (EIA)
    - Basic EIA
- FIGURE 12 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS
  - Alternate EIA Methods
    - Second Antibody Precipitation Method
    - Double Antibody Sandwich Method
    - Reverse Sandwich Method
    - Reverse Sandwich Inhibition Method
    - Reverse Sandwich ý (Continued)
Chapter 8 - BLOOD INDUSTRY: INTERNATIONAL ANALYSIS
- GLOBAL MARKETS FOR WHOLE BLOOD COLLECTIONS
- LOCAL EFFORTS AND IMPROVEMENTS
  - South America
  - Asia
  - Cuba
  - India
  - Pacific Region
    - Australia
    - New Zealand
  - Africa
  - South Africa
  - Canada
  - Europe
    - Austria
    - Britain
    - France
    - Germany
    - Italy
    - Switzerland
    - Turkey
  - Russia
- GLOBAL MARKETS FOR SOURCE PLASMA COLLECTIONS
- TABLE 58 PROJECTED GLOBAL (U.S. AND OTHER MARKETS) PLASMA COLLECTIONS, THROUGH 2012 ($ BILLIONS, MILLIONS LITERS)
  - GLOBAL MARKETS FOR BLOOD THERAPEUTICS
- TABLE 59 PROJECTED WORLD (U.S. AND OTHER MARKETS) SALES OF PLASMA PRODUCTS*, THROUGH 2012 ($ BILLIONS)
  - GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS
- TABLE 60 PROJECTED GLOBAL (U.S. AND OTHER) MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2012($ MILLIONS)
  - GLOBAL MARKETS FOR BLOOD PROCESSING EQUIPMENT AND ASSOCIATED PRODUCTS
- TABLE 61 PROJECTED WORLD SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, THROUGH 2012 ($ MILLIONS)
Chapter 9 - BLOOD RESEARCH AND DEVELOPMENT
- DEDICATED BLOOD RESEARCH FACILITIES
  - JEROME H. HOLLAND LABORATORY (ARC)
- NATIONAL BLOOD FOUNDATION (NBF)
- CENTER FOR BLOOD RESEARCH (CBR)
  - Center for Blood Research (CBR)ý(Continued)
  - Center for Blood Research (CBR)ý(Continued)
  - Center for Blood Research (CBR)ý(Continued)
- TABLE 62 SELECTED ADVANCES IN ADULT STEM CELL THERAPIES
- TABLE 62 (CONTINUED)
  - BLOOD SUBSTITUTES
    - BLOOD SUBSTITUTES (CONTINUED)
  - FIBRIN SEALANT
  - THE VETERINARY BLOOD MARKET
- TABLE 63 REGIONAL VETERINARY BLOOD BANKS
  - THE VETERINARY BLOOD MARKET (CONTINUED)
Chapter 10 - COMPANY PROFILES
- ABBOTT LABORATORIES
- AMERICA' S BLOOD CENTERS
- AMERICAN ASSOCIATION OF BLOOD BANKS (AABB)
- AMERICAN RED CROSS (ARC)
- BAXTER INTERNATIONAL, INC.
- BIO-RAD LABORATORIES
- CSL BEHRING
- GRIFOLS BIOLOGICALS, INC.
- GRIFOLS BIOLOGICALS, INC. (CONTINUED)
- HAEMONETICS, INC.
- IMMUCOR
- MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS
- MEDIMMUNE CORPORATION
- ORTHO-CLINICAL DIAGNOSTICS
- OLYMPUS DIAGNOSTIC SYSTEMS
- TALECRIS BIOTHERAPEUTICS
Chapter 11 - PATENT ANALYSIS
- TABLE 64 RECENTLY ISSUED PATENTS
- TABLE 65 PATENTS BY COMPANY ASSIGNEE
- TABLE 65 (CONTINUED)
Chapter 12 - APPENDIX
- PATENTS
  - BLOOD TRANSFUSIONS-11 PATENTS
    - Blood Transfusions-11 Patents /Continued)
    - Blood Transfusions-11 Patents /Continued)
    - Blood Transfusions-11 Patents /Continued)
    - Blood Transfusions-11 Patents /Continued)
  - BLOOD DERIVATIVES-(SEPTEMBER 1986 TO PRESENT)-SEVEN PATENTS
    - Blood Derivativesý(Continued)
    - Blood Derivativesý(Continued)
    - Blood Derivativesý(Continued)
  - NUCLEIC ACID AMPLIFICATION (MARCH 2000 TO PRESENT) - 40 PATENTS
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
    - Nucleic Acid Amplificationý(Continued)
FDA-LICENSED SOURCE PLASMA FACILITIES
- FDA-LICENSED SOURCE PLASMA ý (CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
  - GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS
    - INTRODUCTION
    - BACKGROUND
    - FDA REVIEW AND CONCLUSIONS
    - REPORTING REQUIREMENTS FOR LICENSED
    - ESTABLISHMENTS
    - SUMMARY

The Blood Industry

Table of Contents